GTBP vs. LGVN, XCUR, CPHI, ARTL, GNPX, ENSC, THAR, NEXI, PTPI, and LIPO
Should you be buying GT Biopharma stock or one of its competitors? The main competitors of GT Biopharma include Longeveron (LGVN), Exicure (XCUR), China Pharma (CPHI), Artelo Biosciences (ARTL), Genprex (GNPX), Ensysce Biosciences (ENSC), Tharimmune (THAR), NexImmune (NEXI), Petros Pharmaceuticals (PTPI), and Lipella Pharmaceuticals (LIPO). These companies are all part of the "pharmaceutical preparations" industry.
Longeveron (NASDAQ:LGVN) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, community ranking, analyst recommendations and dividends.
GT Biopharma received 108 more outperform votes than Longeveron when rated by MarketBeat users. However, 87.50% of users gave Longeveron an outperform vote while only 62.84% of users gave GT Biopharma an outperform vote.
Longeveron presently has a consensus target price of $12.00, suggesting a potential upside of 636.20%. GT Biopharma has a consensus target price of $150.00, suggesting a potential upside of 4,501.23%. Given Longeveron's higher possible upside, analysts clearly believe GT Biopharma is more favorable than Longeveron.
10.0% of Longeveron shares are held by institutional investors. Comparatively, 8.2% of GT Biopharma shares are held by institutional investors. 24.3% of Longeveron shares are held by company insiders. Comparatively, 10.0% of GT Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Longeveron has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, GT Biopharma has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.
GT Biopharma has a net margin of 0.00% compared to GT Biopharma's net margin of -3,020.17%. Longeveron's return on equity of -112.84% beat GT Biopharma's return on equity.
GT Biopharma has lower revenue, but higher earnings than Longeveron. GT Biopharma is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
In the previous week, Longeveron had 4 more articles in the media than GT Biopharma. MarketBeat recorded 4 mentions for Longeveron and 0 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 0.70 beat Longeveron's score of 0.00 indicating that Longeveron is being referred to more favorably in the media.
Summary
GT Biopharma beats Longeveron on 8 of the 15 factors compared between the two stocks.
Get GT Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GTBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GT Biopharma Competitors List
Related Companies and Tools
